| 发明名称 | Hybrid polypeptides with selectable properties | ||
| 摘要 | The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | ||
| 申请公布号 | US9453063(B2) | 申请公布日期 | 2016.09.27 |
| 申请号 | US201414195262 | 申请日期 | 2014.03.03 |
| 申请人 | Amylin Pharmaceuticals, LLC.;AstraZeneca Pharmaceuticals LP | 发明人 | Levy Odile Esther;Hanley Michael R.;Jodka Carolyn M.;Lewis Diana Y.;Soares Christopher J.;Ghosh Soumitra S.;D'Souza Lawrence J.;Parkes David G.;Mack Christine M. |
| 分类号 | A61K38/26;C07K14/605;C07K5/103;C07K5/117;C07K14/575;C07K14/58;A61K9/00;A61K9/19;A61K38/00 | 主分类号 | A61K38/26 |
| 代理机构 | Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. | 代理人 | Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. |
| 主权项 | 1. A polypeptide comprising a bio-active GLP-1 peptide having at least 85% sequence identity to GLP-1(7-37) (SEQ ID NO:204) covalently linked, optionally via a linking group, to a bio-active PYY peptide having at least 85% sequence identity to PYY(3-36) (SEQ ID NO:58); wherein the bio-active GLP-1 peptide is at the N-terminus of the polypeptide and the bio-active PYY peptide is at the C-terminus of the polypeptide. | ||
| 地址 | San Diego CA US | ||